Galectin Therapeutics
GALT
65 hedge funds and large institutions have $37.4M invested in Galectin Therapeutics in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 12 closing their positions.
87% more capital invested
Capital invested by funds: $20M → $37.4M (+$17.4M)
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
7% more funds holding
Funds holding: 61 → 65 (+4)
1.98% more ownership
Funds ownership: 14.08% → 16.06% (+2%)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
25% less call options, than puts
Call options by funds: $2.04M | Put options by funds: $2.71M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.75M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.35M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$964K |
| 4 |
JP Morgan Chase
New York
|
+$906K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$848K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$223K |
| 3 |
Barclays
London,
United Kingdom
|
-$203K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$145K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
-$101K |
GALT Hedge Fund Activity: Q1 2019 in Review
65 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2019, worth a combined $37.4M — up 87% from $20M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new GALT positions and 12 closed out — a net gain of 5 holders — while 15 added to existing stakes and 14 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.75M. The largest seller was Bank of Montreal, cutting an estimated $1M.
- 65 institutional investors held Galectin Therapeutics (GALT) as of Q1 2019, up from 61 in Q4 2018.
- Funds reported $37.4M of Galectin Therapeutics stock for Q1 2019, up 87% quarter-over-quarter.
- 17 funds opened new Galectin Therapeutics positions in Q1 2019 and 12 closed out, a net change of +5 holders.
- The largest Galectin Therapeutics buyer in Q1 2019 was Millennium Management, an estimated $1.75M added.
- The largest Galectin Therapeutics seller in Q1 2019 was Bank of Montreal, an estimated $1M sold.
Based on aggregated 13F filings for Q1 2019.